Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
Duke Chen,1,* Yu-Shen Wu,2,* Huapeng Lin,3,* Yihan Wang,1 Longhao Li,1 Tao Zhang1 1Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affili...
Main Authors: | Chen D, Wu YS, Lin H, Wang Y, Li L, Zhang T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-08-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/efficacy-and-safety-of-tas-102-in-refractory-metastatic-colorectal-can-peer-reviewed-article-CMAR |
Similar Items
-
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
by: Kiyoaki Sugiura, et al.
Published: (2021-04-01) -
Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01) -
Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
by: Sunakawa Y, et al.
Published: (2017-09-01) -
Difference in Neutropenia due to Administration Schedule of TAS-102
by: Yoichiro Yoshida, et al.
Published: (2017-03-01) -
TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study
by: Giuseppe Cicero, et al.
Published: (2020-09-01)